The ACER1 Knockout TE1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for loss-of-function studies of the ACER1 gene in a human esophageal squamous cell carcinoma background. This product provides a heterogeneous pool of TE1 cells harboring targeted disruption of ACER1 via non-homologous end joining, enabling researchers to investigate the functional consequences of ACER1 ablation without clonal selection artifacts. The polyclonal format retains population-level diversity while eliminating wild-type gene expression, making it suitable for sphingolipid metabolism and tumor biology experiments where bulk cellular responses are of primary interest.
Derived from human esophageal squamous cell carcinoma, the TE1 host cell line is a widely used in vitro model for esophageal squamous cell carcinoma, one of the most prevalent and aggressive upper gastrointestinal malignancies. TE1 cells exhibit characteristic epithelial morphology and harbor genomic alterations typical of esophageal squamous cell carcinoma, providing a disease-relevant context for investigating molecular mechanisms driving tumorigenesis, progression, and therapeutic resistance. The integration of ACER1 knockout into this genetic background offers a platform to dissect ceramidase function specifically within esophageal cancer biology.
ACER1 encodes an alkaline ceramidase that hydrolyzes ceramide into sphingosine and a free fatty acid, thereby lowering pro-apoptotic ceramide levels and generating sphingosine, which is subsequently phosphorylated by sphingosine kinase 1 (SPHK1) to sphingosine-1-phosphate (S1P). This enzymatic activity is activated by upstream stimuli including TNF-alpha, IL-1beta, PMA, elevated calcium, and cellular stress, and it shifts the ceramide/S1P rheostat toward pro-survival signaling. Downstream, S1P acts through five G protein-coupled receptors (S1PR1-5) to activate MAPK/ERK and PI3K/AKT pathways, promoting phosphorylation of ERK1/2 and AKT, while also modulating NF-??B. ACER1 functionally interacts with SPHK1, ceramide synthases (CERS1-6), and BCL-2 family proteins, integrating sphingolipid metabolism with apoptotic machinery. By reducing ceramide, ACER1 suppresses ceramide-induced apoptosis, positioning it as a key regulator of cell fate decisions.
In esophageal squamous cell carcinoma, aberrant sphingolipid metabolism is increasingly recognized as a contributor to apoptosis evasion and chemoresistance. ACER1 overexpression has been implicated in increased S1P production, which may drive tumor cell proliferation, migration, and survival through ERK and AKT signaling. The ACER1 Knockout TE1 Polyclonal Cells thus serve as a powerful tool to elucidate how loss of ACER1-mediated ceramide hydrolysis impacts sphingolipid profiles, ceramide accumulation, and downstream signaling in esophageal cancer. This model is particularly valuable for dissecting the crosstalk between ceramide-induced apoptosis and pro-survival S1P signaling in a disease-relevant cellular environment, enabling mechanistic studies that could inform novel therapeutic strategies targeting the sphingolipid pathway.
These knockout cells are ideally suited for a broad range of experimental applications, including sphingolipid metabolism studies using ceramide quantification by LC-MS/MS and sphingosine-1-phosphate ELISA, apoptosis assays such as caspase-3/7 and TUNEL, cell proliferation (MTT) and colony formation assays, Western blot analysis of ACER1, phospho-ERK, and phospho-AKT, RT-qPCR quantification of ACER1 transcript levels, and functional assays for migration and invasion. Researchers can employ this model for drug target validation of ceramidase inhibitors, investigation of chemoresistance mechanisms, and tumor progression analysis. For further details, please contact Ascent Research.
